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Andrew W. Bradbury, BSc, MBA, MD, FRCSEd,a Birmingham, United Kingdom
Background: Abdominal aortic aneurysm (AAA) is a chronic inflammatory condition associated with a prothrombotic,
hypofibrinolytic diathesis that may increase the risk of cardiovascular events. The effect of endovascular aneurysm repair
(EVAR) on this prothrombotic diathesis is not fully understood, especially over the medium and long term. A better
understanding of these postintervention changes may improve the risk of cardiovascular complications in the long term.
The purpose of this study was to examine thrombin generation, fibrinolysis, platelet and endothelial activation, and the
inflammatory response during the 12 months following EVAR.
Methods: Twenty-nine patients (mean age, 76.9 years) undergoing EVAR for AAA (mean diameter 6.9 cm) had
prothrombin fragment (PF) 1  2, thrombin-antithrombin complex (TAT), plasminogen activator inhibitor (PAI)
activity, tissue plasminogen activator (t-PA) activity and antigen, soluble P- and E-selectin, and highly sensitive C-reactive
protein (hsCRP) measured before and at 24 hours, and 1, 6, and 12 months after surgery.
Results: PF1  2 were markedly elevated prior to EVAR and remained so at 24 hours and 1 month, but had decreased
significantly at 6 and 12 months. TAT was also elevated prior to EVAR and increased still further by 24 hours, but fell
to below baseline levels thereafter. PAI activity and t-PA antigen were normal prior to EVAR, increased significantly at
24 hours, and then fell to baseline levels. t-PA activity was only detectable at 1 and 6 months; there was a significant rise
in soluble P- and E-selectin after EVAR, which was sustained for 12 months. hsCRP increased transiently in response to
EVAR but returned to preoperative levels by 1 month.
Conclusions: The prothrombotic, hypofibrinolytic diathesis associated with AAA is normalized 12 months after EVAR.
This beneficial systemic effect of EVAR for AAA disease may help protect patients against future thromboembolic
cardiovascular events. ( J Vasc Surg 2012;55:41-6.)
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kAbdominal aortic aneurysm (AAA) is associated with
deranged hemostasis, endothelial cell (EC) and platelet
activation, and cardiovascular morbidity and mortality.1-14
A recent work from this group has shown that patients with
AAA exhibit increased thrombin generation and activity as
well as increased fibrin turnover.15 Although these de-
rangements appear to be correlated with aneurysm size,14
increased fibrin turnover is also found in patients with small
AAA.1 This may show that hemostatic derangement is
related to the size of intrasac thrombus than aneurysm
size.16
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doi:10.1016/j.jvs.2011.07.094Both open surgical (OR) and endovascular (EVAR)
epair of AAA are associated with increased thrombin gen-
ration and relative hypofibrinolysis in the immediate peri-
perative period.13,15,17-21 The resultant prothrombotic
iathesis after OR and EVARmay account for the high level
f peri-operative thrombotic complications.15 It was found
hat the hemostatic response is significantly reduced in the
ong term followingOR but not normalized.22However, it
emains unclear what happens in the long term following
VAR and what the clinical consequences of these hemo-
tatic abnormalities might be for patients. The aim of this
tudy, therefore, was to examine thrombin generation,
brinolysis, and EC and platelet activation for up to 12
onths following elective EVAR.
ETHODS
Patients. Ethical approval was obtained. Patients un-
ergoing EVAR and who were willing and able to give fully
nformed written consent were prospectively recruited. Ex-
lusion criteria were vascular or nonvascular surgical or
ndovascular procedure within the 3 months prior to
VAR; known inherited or acquired thrombophilia;
nown disorders of fibrinolysis or platelet function; and
nticoagulation therapy with vitamin K antagonists.
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January 201242 Abdelhamid et alBetween July 2008 and April 2009, 35 patients had
elective EVAR. Two patients refused to participate in the
study, and two were on anticoagulation and were excluded.
The remaining 31 patients were recruited. One patient
withdrew from the study on the first postoperative day and
one died of massive myocardial infarction 3 months after
the operation. Twenty-nine patients (27 men and 2 fe-
males) of mean age 77 years (range, 55-89 years) and with
AAA of mean diameter 6.9 cm (range, 5.5-10 cm) under-
went 19 standard and 10 fenestrated EVARs under general
(n  12) or epidural (n  17) anesthesia. All patients
received bolus injection of intravenous heparin (3000 units
for standard and 5000 units for fenestrated EVAR) prior to
inserting the stent graft. Twenty-two patients were taking
aspirin (75 mg daily), 14 were being treated for hyperten-
sion, 16 had a history of ischemic heart disease, and 14 had
renal impairment (Table I).
Venous blood was collected from the antecubital fossa
without tourniquet into sodium citrate tubes before induc-
tion of anesthesia and at 1 day and 1, 6, and 12 months
postoperatively. Samples were centrifuged for 15 minutes
at 3500 revolutions per minute within 30 minutes of col-
lection; plasma was isolated, aliquoted, and stored at
80°C for later batch analysis.
Markers of thrombin generation and neutralization.
Prothrombin fragment (PF) 1  2 (USCN Life Science
Inc, Wuhan, China) and thrombin-antithrombin com-
plexes (TAT; Enzygnost TAT Micro, Siemens Healthcare
Diagnostics Inc, Deerfield, Ill) were measured (Fig 1).
Markers of fibrinolysis. Plasminogen activator inhib-
itor (PAI) activity (Technozym PAI-1 Actibind; Techno-
clone Ltd, Surrey, United Kingdom) and tissue plasmino-
gen activator (t-PA) antigen and activity (t-PA Combi
Actibind; Technoclone Ltd) were measured (Fig 2).
Markers of platelet and endothelial activation and
inflammation. Soluble (s)P-selectin was measured as a
Table I. Patients’ demographics
Mean age (range) 76.9 years (55.2-88.5)
75 years (%) 18 (62.1%)
75 years (%) 11 (3.9%)
Gender (M:F) 27:2 (93.1%: 6.9%)
Hypertension (%) 14 (48.3%)
Ischemic heart disease (%) 16 (55.2%)
Chronic kidney disease (%) 14 (48.3%)
Mean aneurysm size (range) 6.9 cm (5.5-10)
Aneurysm anatomy (%)
Infra-renal 19 (65.5%)
Endovascular aneurysm repair (%)
Standard 19 (65.5%)
Fenestrated 10 (34.5%)
Anesthesia
General 12 (41.4%)
Epidural 17 (58.6%)
Make of stent (%)
Zenith 23 (79.3%)
Excluder 6 (20.7%)
Patients on antiplatelets (aspirin) (%) 22 (75.9%)marker of platelet activation, sE-selectin as a marker of EC wctivation23,24 (IBL International GMBH,Hamburg, Ger-
any), and highly sensitive C-reactive protein (hs-CRP)
as measured as a marker of the inflammatory response.
Tests were performed using the fully automated, multi-
atch and multi-test Triturus EIA Analyzer (Grifols USA,
LC, Los Angeles, Calif) according to the manufacturer’s
nstructions.
Statistical analysis. The groups were compared us-
ng the Friedman test. Changes in variables over time
ig 1. Mechanism of the coagulation system. Tissue injury, en-
othelial activation and injury, and monocyte activation lead to
issue factor release. This triggers the extrinsic coagulation cascade.
his results in conversion of prothrombin into thrombin and
rothrombin fragment (PF) 1  2. Thrombin is inactivated by
ntithrombin III, leading to formation of thrombin-antithrombin
omplex (TAT).
ig 2. Mechanism of the fibrinolytic system. Endothelial activa-
ion and injury causes the release of tissue plasminogen activator
t-PA) antigen, which converts plasminogen into the active plas-
in. This active enzyme leads to the breakdown of fibrinogen,
brin, and fibrin clot to fibrin degradation products. Plasminogen
ctivator inhibitor (PAI) is released from the endothelium, hepa-
ocytes, and platelets to inhibit t-PA.ere analyzed using Dunn’s multiple comparison test
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Volume 55, Number 1 Abdelhamid et al 43and Wilcoxon signed rank paired test. Because data were
not normally distributed, they were log transformed to
determine the effects of covariables on the results using
the parametric independent-sample t test.
Calculations were performed using SPSS for Win-
dows (version 16.0; SPSS Inc, Chicago, Ill) and Graph-
Pad Prism 5 for Windows (version 5.03; GraphPad Soft-
ware Inc, La Jolla, Calif). A P value of less than 0.05 was
considered statistically significant. Unless specified oth-
erwise, median and interquartile ranges (IQR) were
used.
RESULTS
Patients and stent grafts
All stent grafts (23 Zenith; Cook Inc, Bloomington,
Ind and 6 Excluder; W. L. Gore Inc, Flagstaff, Ariz) were
implanted successfully. No patient required peri-operative
blood transfusion.
Three patients required reintervention at 6 months for
claudication; two underwent angioplasty and a third had
common femoral artery endarterectomy and angioplasty.
Two other patients developed asymptomatic type II en-
doleaks, which were treated conservatively. Changes in
hemostatic, endothelial, platelet, and inflammatory mark-
ers are summarized in Table II.
Markers of coagulation
PF 1  2 did not change significantly from baseline to
either 24 hours or 1 month, but there was a significant fall
by 6 and 12 months (Fig 3, A).
TAT increased significantly at 24 hours postopera-
tively, followed by return to the preoperative levels at 1, 6,
Table II. Changes in different markers over time (median
Preoperative median
(IQR)
24 Hours m
(IQR
Prothrombin fragment 1  2
(0.4-1.1 nmol/L) 2.1 (1.5-3.7) 2 (1.4-2
Thrombin-antithrombin
complex (1-4.1 g/L) 6.2 (4.4-15.6) 14 (11-2
Plasminogen activator inhibitor
activity (1-7 U/mL) 4.9 (0.3-6.8) 8.5 (0.3-1
Tissue plasminogen activator
antigen (2-8 ng/mL) 3.4 (2.6-4.4) 5.1 (3.1-6
Tissue plasminogen activator
activity (0 U/mL) mean
(SD) 0 (0) 0 (0)
sP-selectin (92-212 ng/mL) 71 (61-86) 80 (61-9
E-selectin (17.5-88.1 ng/mL) 14 (9-18) 24.5 (12.5
Highly sensitive C-reactive
protein (mg/L) 4.3 (1.5-12.75) 82.2 (53-1
IQR, Interquartile range; SD, standard deviation.
aP  .05 against preoperative values.and IQR)
edian
)
1 Month median
(IQR)
6 Months median
(IQR)
12 Months median
(IQR)
.9) 2.1 (1.6-3.4) 1.9 (1.2-2.5)a 1 (0.7-2)a
4.6)a 8.1 (5.4-14.3) 8.9 (5.1-11.6) 7 (5.1-11)
0.6)a 0.3 (0.3-3)a 0.3 (0.3-4)a 5.7 (3.8-7.7)
.4)a 3.5 (2.4-5.4) 1.2 (1-2.2)a 3.4 (2.4-4.5)
0.046 (0.09)a 0.023 (0.06)a 0 (0)
3) 113 (80-141.5)a 110 (73.5-139.5)a 87 (61-116)a
-42.5)a 15 (9-22) 52 (23.5-59.5)a 38 (24-42)a
05.5)a 7 (3.3-19) 4.3 (2.1-16.3) 2.7 (1.2-11.6)and 12 months postoperatively (Fig 3, B). sig 3. (A) Changes in prothrombin fragment (PF) 12. (B)
hanges in thrombin-antithrombin complex (TAT). Horizontal
ines represent the normal range (manufacturer’s range). Error bars
epresent the minimum and maximum and the rectangles repre-
ent the median and interquartile range (IQR).
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PAI activity increased significantly at 24 hours, fol-
lowed by a significant drop at 1 and 6 months. At 12
months, there was a significant increase in PAI, leading to a
return to the preoperative levels (Fig 4, A).
t-PA antigen increased significantly at 24 hours and
then returned to the baseline level at 1 month. This was
followed by a significant reduction at 6months and a return
to preoperative values at 12 months (Fig 4, B).
t-PA activity was unchanged at 24 hours, followed by a
significant increase at 1 and 6 months and a return to
preoperative level at 12 months.
Platelet activation. sP-selectin did not change at 24
hours, but at 1 month there was a significant elevation that
was sustained at 6 months. There was a significant drop at
12 months, but the median value was significantly higher
than preoperatively. Patients with ischemic heart disease
and those who were on antiplatelet treatment before the
Fig 4. (A) Changes in plasminogen activator inhibitor (PAI)
activity. (B) Changes in tissue plasminogen activator (t-PA) anti-
gen.operation had significantly lower sP-selectin levels. EEndothelial activation. sE-selectin increased signifi-
antly at 24 hours, followed by return to preoperative value
t 1 month and a significant increase at six and 12 months
Fig 5).
Inflammatory response. hsCRP increased signifi-
antly at 24 hours and then returned to baseline level at 1
onth and did not change significantly at 6 or 12 months.
atients with infra-renal AAA had significantly lower pre-
perative hsCRP (P  .003). When the inflammatory
esponse to EVAR was compared between patients, those
ho had fenestrated EVAR had a significantly higher re-
ponse at 1 (P  .012), 6 (P  .009), and 12 (P  .021)
onths than patients who had standard EVAR.
Correlation of different markers, aneurysm size and
emographics. Aneurysm size did not correlate with co-
gulation, fibrinolytic, or inflammatory markers pre- or
ostoperatively. TAT and PF1 2 did not correlate at any
ime point. PAI activity correlated significantly with t-PA
ntigen at all time points (P  .001). sP-selectin and
Fig 5. (A) Changes in sP-selectin. (B) Changes in sE-selectin.-selectin did not correlate at any time point.
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Previous case reports have described disseminated in-
travascular coagulopathy (DIC) following EVAR.25,26 It
has been suggested that continued perfusion of a throm-
bus-filled aneurysm sac might predispose to an acute-on-
chronic consumptive coagulopathy.27,28
The present study confirms that patients with asymp-
tomatic AAA exhibit a prothrombotic diathesis character-
ized by excessive thrombin generation as shown by mark-
edly elevated PF1 2 and TAT prior to EVAR.4,15,17,19-22
However, unlike some previous studies, no correlation was
found between TAT, PF1  2, and aneurysm diameter in
this cohort.
The different behavior of PF1 2 and TAT in response
to EVAR and the lack of correlation between these two
markers before and after the operation suggest they repre-
sent different responses (Fig 3). High levels of PF1 2 and
TAT indicate excess thrombin production and neutraliza-
tion, respectively. PF1  2 remained unchanged from
baseline at 24 hours and 1 month postoperatively, indicat-
ing no increase in thrombin generation in response to
EVAR. At 6 months, it decreased significantly; however, it
was still higher than the normal range. At 12 months,
PF1 2 dropped significantly below the preoperative level
to reach normal values, suggesting normalization of throm-
bin generation at 1 year post-EVAR. This indicates that the
presence of the thrombus in the isolated aneurysm sac does
not induce thrombin production as previously sug-
gested.20,29
The significant increase in TAT at 24 hours postoper-
atively may be explained by increased binding with anti-
thrombin III in response to manipulation during insertion
of the stent graft. Shimazaki et al18 and Monaco et al21
showed a significant reduction in antithrombin III and a
significant increase in TAT on the first postoperative day.
They showed return of antithrombin III to baseline on the
first week after the operation, which then remained un-
changed. Results similar to ours were observed at short-
term in previous studies.17,18,20
This is the first report to describe normalization of
thrombin generation detected 1 year following EVAR. The
combination of no increase in thrombin generation and
increased thrombin neutralization following EVARmay be
protective against cardiovascular complications and throm-
boembolic disorders in this group of patients.
Similar to previous studies, we found preoperative PAI
activity and t-PA antigen and activity to be within the
normal range.14,17,19 While one might conclude that this
indicates normal fibrinolysis, given the very high levels of
thrombin generation, one might expect fibrinolysis to be
activated with elevated t-PA activity and reduced PAI ac-
tivity. That this appears not to be the case suggests that, in
fact, these AAA patients have relative hypofibrinolysis that
might further predispose them to thrombotic problems.
Indeed, PAI activity increased significantly to above the
normal range on the first postoperative day, following Ohich levels dropped below baseline levels (although most
alues were still in the normal range). Aho et al17 described
significant increase in PAI activity at day 1 postopera-
ively, temporary decrease at day 3, increase again at day 7,
nd return to preoperative levels at 3 months. The postop-
rative fibrinolytic response showed low fibrinolytic activity
n the first postoperative day, which may be due to the
urgical trauma, high fibrinolytic activity at 1 and 6months,
nd return to normal fibrinolytic activity 12months follow-
ng EVAR. The expected correlation between PAI activity
nd t-PA antigen at all time points indicates the validity of
he analysis (Fig 4).
The significant increase in platelet activity, as repre-
ented by elevated sP-selectin during the first postoperative
ear, may justify giving dual antiplatelet therapy to patients
ollowing EVAR, especially during the first year after the
peration. Aho et al described a significant reduction in
P-selectin on the third postoperative day, with increase
bove the baseline 3 months following EVAR.17 The sig-
ificant increase in sE-selectin that was observed on the first
ostoperative day could be due to the manipulation during
nsertion of the stent graft. The absence of correlation
etween sP- and sE-selectin at all time points and their
ifferent responses to EVARmay indicate that they did not
rise from the same source (Fig 5).
The increase in hsCRP demonstrated on day 1 oc-
urred in response to the surgical trauma. However, there
as no significant difference in the inflammatory response,
rom the baseline level, at 1, 6, and 12 months postopera-
ively. Previous studies have detected the maximum in-
rease in CRP on the second and third days following
VAR.17,20 The significantly lower hsCRP in patients with
nfra-renal AAA preoperatively and the higher response in
atients who had fenestrated EVAR postoperatively may
ndicate that the inflammatory response is related to the
xtent of the aneurysm rather than the size. A correlation
etween CRP and the volume of the intramural thrombus
as been previously described.17
In conclusion, this report shows, for the first time, that
he prothrombotic, hypo-fibrinolytic diathesis associated
ith AAA is normalized 12 months after EVAR. This
eneficial systemic effect of EVAR for AAA disease may
elp protect patients against future thromboembolic car-
iovascular events.
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